Melatonin use during pregnancy and lactation: A scoping review of human studies.
Study Goal
The researchers aimed to critically review human studies on the safety and use of exogenous melatonin during pregnancy and breastfeeding.
Results Summary
The review found no major safety concerns or adverse events from melatonin use during pregnancy and breastfeeding, though efficacy for sleep disorders was not directly assessed due to lack of focused studies.
Population
Pregnant and breastfeeding individuals
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
exogenous melatonin | no change | use during pregnancy | pregnant populations | about 4% | use is quite common | #1 |
exogenous melatonin | no change | safety | during pregnancy and breastfeeding | null | have not suggested major safety concerns or adverse events | #2 |
exogenous melatonin | no change | safety | during pregnancy and breastfeeding in humans | null | is probably safe | #3 |
OBJECTIVE: The prevalence of sleep disorders during the perinatal period is high and large health administrative database surveys have shown that the use of exogenous melatonin in pregnant populations is quite common, about 4%. Much of the concern about using melatonin during pregnancy and breastfeeding stems from animal research. Thus, the objective of this article is to provide a critical review of human studies related to exogenous melatonin use during pregnancy and breastfeeding. METHODS: The electronic databases Ovid, MEDLINE, Embase, and the Cochrane Library were searched using terms and keywords related to melatonin, pregnancy, and breastfeeding. RESULTS: Fifteen studies were included in this review. Eight focused on melatonin use during pregnancy and seven focused on melatonin use during breastfeeding. There was a variety of study designs, including case reports, cohort studies, and clinical trials. There is a lack of randomized, controlled trials examining the efficacy and safety of melatonin as a treatment for sleep disorders during pregnancy or breastfeeding and, notably, insomnia was not the primary outcome measure in any of the studies included in this review. Clinical trials that used exogenous melatonin during pregnancy and breastfeeding for other clinical conditions have not suggested major safety concerns or adverse events. CONCLUSION: Contrary to what animal studies have suggested, evidence from clinical studies to date suggests that melatonin use during pregnancy and breastfeeding is probably safe in humans. This review further emphasizes the need for clinical studies on sleep disorders, including exogenous melatonin, during pregnancy and lactation.